AcuNova Life Sciences, a subsidiary of the Bangalore-based Manipal AcuNova, has entered into a strategic collaboration with KCR, (Kiecana Clinical Research) which is based in Warsaw, Poland for leveraging operations in South Asia, Europe and Latin America.
The alliance has resulted in the formation of a regional expert CRO aimed at quality clinical trials conducted on time, at competitive costs. It will focus on therapeutic areas like oncology, cardio-vascular, endocrinology and neurology for phase I-IV trials.
Over 250 professionals including 39 MD's and 12 PhD, will combine their therapeutic expertise, It will also offers to clients high quality Data Management and Biostatistics service, as well as conduct of PK/PD studies.
The primary objectives of the pact are to increase patient recruitment in newer regions like East Europe for AcuNova clients and South Asia and Latin America for KCR clients. The FDA submission expertise would be available to AcuNova and CDM/Biostatistics for KCR. The collaboration will add value to clients to expand their trials to newer markets, thereby increasing speed and reducing risks, stated Marek Kiecana, President, KCR.
According to D A Prasanna, vice chairman, AcuNova Life Sciences, international clients are more at ease with CRO's that have multi region presence and offer end-to-end service. We are able to address this need, with KCR highly reputed CRO in Central and East Europe.
Manipal AcuNova Ltd is a comprehensive, single source provider of clinical research and related services to Pharma, Bio-Pharma and Medical device companies. Services are offered in Bio Availability and Bio Equivalence studies, Phase I - IV clinical trials, clinical data management and the central Lab. The company bagged India's No 1 emerging CRO in 2005 from Proximare Inc., a New Jersey based strategic Consulting firm).
KCR is a European drug development company which offers a complete range of clinical development and consulting services to the Pharmaceutical and Biotech industries. It specializes in conducting phase II - IV in Europe, especially in Central and Eastern Europe.A team of over 100 project managers, CRA's, and other specialists in drug development are located across Europe. The company has conducted more than 150 clinical trials with a focus of key therapeutic areas like CNS, cardiology, diabetology, oncology, rheumatology, psychiatry and infectious diseases.